Haohai Biotechnology (06826) rose more than 7%. As of press release, it had risen 7.2% to HK$40.2, with a turnover of HK$5.797,700.
The Zhitong Finance App learned that Haohai Biotechnology (06826) rose by more than 7%. As of press release, it had risen 7.2% to HK$40.2, with a turnover of HK$5.797,700.
According to the news, Haohai Biotech announced its annual results for the year ended December 31, 2023, with operating income of 2,6349 million yuan (RMB, same below), an increase of 25.27% over the previous year; net profit attributable to shareholders of listed companies was 416 million yuan, an increase of 130.58% over the previous year. The proposed final dividend is RMB 1.00 per share (tax included), and it is proposed to issue 4 new shares to shareholders for every 10 shares of the company's existing shares from reserves.
According to the announcement, the company's overall gross margin during the period was 70.34%, up from 68.79% in 2022, mainly driven by the increase in operating income of high-margin hyaluronic acid products and their share of the Group's revenue. Debon Securities pointed out that Haohai Biotech is a leading biomedical materials company, building pipelines such as “injection filling+photoelectric instrument+botulic+collagen”, collecting artificial lenses “in exchange for price”, and is optimistic about “medical+pharmaceutical” two-wheel drive.